Developments in L2-based human papillomavirus (HPV) vaccines. - Wikidata - awgldk - TriplyDB

Developments in L2-based human papillomavirus (HPV) vaccines.

Developments in L2-based human papillomavirus (HPV) vaccines.

http://www.wikidata.org/entity/Q39021001

about

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus.Expanded strain coverage for a highly successful public health tool: prophylactic 9-valent human papillomavirus vaccine.Current status and future prospects for human papillomavirus vaccines.Immunization of mice by a multimeric L2-based linear epitope (17-36) from HPV type 16/18 induced cross reactive neutralizing antibodies.Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles.Antibody Competition Reveals Surface Location of HPV L2 Minor Capsid Protein Residues 17-36.Minor capsid protein L2 polytope induces broad protection against oncogenic and mucosal human papillomaviruses.Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.

P2860

Q36240497-AF21468E-D7FF-47FD-A3FB-11A8B3230976 Q38635840-AABE3C8C-6444-4D38-BCD4-84477F16457C Q38682763-13BD9A1F-09A0-4BD7-9199-6E332DA1822C Q40056541-AD30B73B-511E-4DD6-842F-FE7BC2B2346A Q40064084-6AB3A6C2-135B-4BEA-8D87-F2CDD8C309A3 Q47110564-74782B6E-A0DF-4D41-9F2B-68B689A7D69A Q47143249-C85C32AA-96AE-40A1-97A2-621D6F37F8D1 Q47322093-B8861367-CE8B-4DFE-A939-C01124AA7BC9 Q55054189-4937D830-4A22-425F-A52C-0FF3FBACA5BD Q55215825-B455199D-7422-44F1-8B9A-ACF2D54F2546

P2860

Developments in L2-based human papillomavirus (HPV) vaccines.

http://www.wikidata.org/entity/Q39021001

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Developments in L2-based human papillomavirus (HPV) vaccines.

@en

Developments in L2-based human papillomavirus

@nl

type

label

Developments in L2-based human papillomavirus (HPV) vaccines.

@en

Developments in L2-based human papillomavirus

@nl

altLabel

Developments in L2-based human papillomavirus (HPV) vaccines

@en

prefLabel

Developments in L2-based human papillomavirus (HPV) vaccines.

@en

Developments in L2-based human papillomavirus

@nl

P1433

Q39021001-3CBE7E9B-69E3-4802-9748-1B6DB2CD5C72

P1476

Q39021001-71BB62B5-323A-469E-83AF-25F1D3C01F8F

P2093

Q39021001-069C484F-7BD1-4E2E-A7C9-9EA54FBBC3F6

Q39021001-5EAF78DB-58D4-42E1-A4BA-F255BE37DBB3

Q39021001-A02F0F97-102B-4EA3-8B25-691313E3FAF6

P2860

Q39021001-07A19390-25FE-4BD4-93E2-21CB0D27E410

Q39021001-08568D2F-1184-4026-A536-90508C0F8090

Q39021001-10667E03-FB86-44A1-B1F5-17A4367015A6

Q39021001-129E5B3D-D97C-4B94-B755-053642E4DA4D

Q39021001-14C74FD7-D8D5-48AE-8726-5BDBAE9DDBF9

Q39021001-192D8A38-AB64-40D0-AA16-00A0DB3AB3C9

Q39021001-1A808210-AB4E-478A-A289-1C604B68A926

Q39021001-1B5282B0-E7EE-4C01-B721-FC02D441CBA8

Q39021001-1B784DD1-CA00-4C22-9272-F1B2EBCFB8DB

Q39021001-2377292C-72C7-4961-8B6A-A446061302AE

P304

Q39021001-B5DAC221-4639-4791-843E-692AE5F24DAF

P31

Q39021001-AE9DFEE2-3B7A-492F-A800-872FC3610A39

P356

Q39021001-34A737A5-E384-4424-A56A-DCEBE8A1F2A3

P407

Q39021001-E18061A0-A9E8-47A2-B3E1-28B9829D2A52

P478

Q39021001-BC4A35A7-F6DE-47ED-85DD-6908E57D2435

P577

Q39021001-0DFAEE85-DC9F-41E8-ABFD-42F988270A34

P698

Q39021001-39F19B08-E2DB-48D3-A32A-2B9652309873

P921

Q39021001-52A649C8-B1DC-478C-ABA4-B82F772E2F00

Q39021001-AC0281F8-9B7E-482F-B7E0-979B5AF8268D

Q39021001-DB77ED3A-7840-42C3-BCE6-C873D86A24EF

P932

Q39021001-E35FE1B1-5A54-41D1-A661-356B8903FA2C

P356

J.VIRUSRES.2016.11.020

P1433

P1476

Developments in L2-based human papillomavirus (HPV) vaccines.

@en

P2093

Christina Schellenbacher

http://www.w3.org/2001/XMLSchema#string

Reinhard Kirnbauer

http://www.w3.org/2001/XMLSchema#string

Richard B S Roden

http://www.w3.org/2001/XMLSchema#string

P2860

Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review

Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate

Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection

Gavi HPV Programs: Application to Implementation

Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus

Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes

P304

166-175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VIRUSRES.2016.11.020

http://www.w3.org/2001/XMLSchema#string

P407

P478

231

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27889616

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

cancer research

P932

5549463

http://www.w3.org/2001/XMLSchema#string